A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study.

A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study.

Item
http://www.wikidata.org/entity/Q33418532
Aurora Kinase Inhibitors: Current Status and OutlookStructural insights into the polypharmacological activity of quercetin on serine/threonine kinasesEarly phase clinical trials of anticancer agents in children and adolescents - an ITCC perspective.Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology EuroAn update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitor.A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia.Multi-kinase inhibitors, AURKs and cancer.Lentivirus mediated silencing of ubiquitin specific peptidase 39 inhibits cell proliferation of human hepatocellular carcinoma cells in vitro.A population pharmacokinetic model of AT9283 in adults and children to predict the maximum tolerated dose in children with leukaemia.Advances in emerging drugs for the treatment of neuroblastoma.Identification of ponatinib and other known kinase inhibitors with potent MEKK2 inhibitory activity.Medulloblastoma in children and adolescents: a systematic review of contemporary phase I and II clinical trials and biology update.Recent Advances of Cell-Cycle Inhibitor Therapies for Pediatric Cancer.Combined chemical genetics and data-driven bioinformatics approach identifies receptor tyrosine kinase inhibitors as host-directed antimicrobials.The unpredictable Northern light: The rise and fall of the aurora kinase inhibitors?
P2860

A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study.

Item
http://www.wikidata.org/entity/Q33418532
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A phase I trial of AT9283 (a s ...... s: a Cancer Research UK study.
@ast
A phase I trial of AT9283 (a s ...... s: a Cancer Research UK study.
@en
type
label
A phase I trial of AT9283 (a s ...... s: a Cancer Research UK study.
@ast
A phase I trial of AT9283 (a s ...... s: a Cancer Research UK study.
@en
prefLabel
A phase I trial of AT9283 (a s ...... s: a Cancer Research UK study.
@ast
A phase I trial of AT9283 (a s ...... s: a Cancer Research UK study.
@en
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
A phase I trial of AT9283 (a s ...... s: a Cancer Research UK study.
@en
P2093
P304
P31
P356
10.1158/1078-0432.CCR-14-1592
P407
P433
P478
P50
P577
P698
P921